-
1 Comment
Autek China Inc is currently in a long term uptrend where the price is trading 46.9% above its 200 day moving average.
From a valuation standpoint, the stock is 625.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 69.9.
Autek China Inc's total revenue rose by 63.1% to $264M since the same quarter in the previous year.
Its net income has increased by 101.0% to $156M since the same quarter in the previous year.
Finally, its free cash flow grew by 105.4% to $95M since the same quarter in the previous year.
Based on the above factors, Autek China Inc gets an overall score of 4/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100002MR0 |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Market Cap | 14B |
|---|---|
| PE Ratio | 28.04 |
| Target Price | 17.81 |
| Dividend Yield | 1.7% |
| Beta | 0.8 |
Autek China Inc. engages in the research and development, production, and sale of hard contact lens products in China. The company offers rigid contact lenses, rigid lens care products, myopia control products other than rigid glasses, visual function training products, dry eye/eye strain/presbyopia/accommodative hypoplasia treatment products, and eye health products. It also provides ophthalmic and optometry medical devices. In addition, the company offers ophthalmic optometry technology services. Autek China Inc. was incorporated in 2000 and is based in Hefei, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300595.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
